News Releases

View All Resources

TriGemX Bio Announces $94M Financing and Initiation of Phase 3 Trials for Elismetrep, A Potential First-in-Class Treatment for Migraine

October 1st, 2026

Kallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific Meeting

June 4th, 2026

Kallyope’s Phase 2b Study of Elismetrep, A Novel Approach for Treating Migraine, Presented at the American Academy of Neurology Annual Meeting

April 22nd, 2026

Kallyope to Present Phase 2b Study Results for Elismetrep for the Acute Treatment of Migraine at the 2026 American Academy of Neurology Annual Meeting

March 5th, 2026

Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine

December 8th, 2025